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Abstract
Guidance concerning tyrosine kinase inhibitors (TKIs) for patients with wild type epidermal growth factor receptor
(EGFR) and advanced nonesmall-cell lung cancer (NSCLC) after ﬁrst-line treatment is unclear. We assessed the effect
of TKIs as second-line therapy and maintenance therapy after ﬁrst-line chemotherapy in two systematic reviews and
meta-analyses, focusing on patients without EGFR mutations. Systematic searches were completed and data
extracted from eligible randomized controlled trials. Three analytical approaches were used to maximize available
data. Fourteen trials of second-line treatment (4388 patients) were included. Results showed the effect of TKIs on
progression-free survival (PFS) depended on EGFR status (interaction hazard ratio [HR], 2.69; P ¼ .004). Chemo-
therapy beneﬁted patients with wild type EGFR (HR, 1.31; P < .0001), TKIs beneﬁted patients with mutations (HR,
0.34; P ¼ .0002). Based on 12 trials (85% of randomized patients) the beneﬁts of TKIs on PFS decreased with
increasing proportions of patients with wild type EGFR (P ¼ .014). Six trials of maintenance therapy (2697 patients)
were included. Results showed that although the effect of TKIs on PFS depended on EGFR status (interaction HR,
3.58; P < .0001), all beneﬁted from TKIs (wild type EGFR: HR, 0.82; P ¼ .01; mutated EGFR: HR, 0.24; P < .0001).
There was a suggestion that beneﬁts of TKIs on PFS decreased with increasing proportions of patients with wild type
EGFR (P ¼ .11). Chemotherapy should be standard second-line treatment for patients with advanced NSCLC and wild
type EGFR. TKIs might be unsuitable for unselected patients. TKIs appear to beneﬁt all patients compared with no
active treatment as maintenance treatment, however, direct comparisons with chemotherapy are needed.
Clinical Lung Cancer, Vol. 16, No. 3, 173-82 ª 2015 The Authors. Published by Elsevier Inc. All rights reserved.
Keywords: Chemotherapy, Meta-analysis, NSCLC, RCT, TKIIntroduction
After reports of clinical trials1-5 and clinical guidelines (National
Institute for Health and Care Excellence [NICE] TA258 and Na-
tional Comprehensive Cancer Network [NCCN] Non-Small-Cell
Lung-17), the use of the tyrosine kinase inhibitors (TKIs), erlotinib*This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/).
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http://dx.doi.org/10.1016/j.cllc.2014.11.007and geﬁtinib, is now common practice for ﬁrst-line treatment of
patients with nonesmall-cell lung cancer (NSCLC) with sensitizing
epidermal growth factor receptor (EGFR) mutations. Beyond ﬁrst-
line treatment, in particular for patients with wild type EGFR who
have received ﬁrst-line chemotherapy, recommendations regarding
the potential beneﬁts of TKIs are less clear (NICE TA162, NCCN
Guidelines for NoneSmall-Cell Lung Cancer).6,7
With the exception of a few modern trials that only recruited
patients with wild type disease,8,9 most evaluations of these drugs
have been in unselected patients. Many of these trials did not test
for EGFR mutations systematically, therefore, their results are re-
ported either for all randomized patients, ignoring EGFR mutation
status, or for the subset of patients in whom the status was known.
Results of these trials are mixed and interpretation difﬁcult.
Similarly, attempts have been made to synthesize existing data, to
inform clinical guidelines and practice. Some have pooled allClinical Lung Cancer May 2015 - 173
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174 -available results irrespective of mutation status or treatment
line.10,11 This approach gives results based on large numbers of
randomized patients, but results are difﬁcult to interpret. Others
have attempted to summarize the results of trials within subgroups
deﬁned according to EGFR status.12,13 Although this seems sensible
and offers a more meaningful interpretation of the results, there are
clear drawbacks. For example, trials that did not report their results
according to mutation status were excluded, as were patients for
whom no EGFR testing was carried out. When only a subset of the
randomized patients within a given trial were tested, pooling results
might introduce bias,14 not least because we cannot be certain that
these patients were representative.
Despite these difﬁculties, there is a need to obtain effective and
reliable summaries of the effects of TKIs in patients with and without
sensitizing EGFR mutations after ﬁrst-line treatment. Therefore, we
set out to take into account the potential issues and biases. Rather than
relying on one analytical approach, we planned a number of separate
analyses. In addition to pooled analyses of all patients from all trials
and of patient subgroups deﬁned according to EGFR status, we aimed
to carry out appropriate tests of interaction between treatment effects
and patient characteristics, namely mutation status, to ascertain
whether effects differed between patient groups. Finally, by assuming
the likely ratios of patients with wild type and mutated EGFR in trials
based on geographical location (East Asia 60:40/rest of world
90:10),15 we could assess the effect of increasing proportions of wild
type patients on the overall treatment estimates using metaregression.
Interpretation of the results was not based on any one of the individual
results from the 3 approaches but on the combined results of all 3
approaches, such that we could feel more conﬁdent in our interpre-
tation when results from all 3 analyses were complementary. Analyses
were carried out in trials of second-line treatment, when TKIs were
compared with standard chemotherapy regimens and in the mainte-
nance therapy setting, compared with no active treatment.
Materials and Methods
All methods were prespeciﬁed in 2 registered protocols
(CRD42013006449 and CRD42013006251).
Included trials should have randomized patients with advanced
NSCLC irrespective of sex, age, histology, ethnicity, smoking his-
tory, or EGFR mutational status. Patients should not have received
previous TKIs. For the systematic review of second-line treatment,
trials should have compared a TKI (erlotinib or geﬁtinib) versus
chemotherapy after ﬁrst-line chemotherapy. For maintenance
treatment, trials should have compared a TKI (erlotinib or geﬁtinib)
versus no TKI after ﬁrst-line chemotherapy.
Systematic searches16 were conducted in MedLine, EMBASE,
Cochrane CENTRAL, clinical trials registers (PDQ, ClinicalTrials.
gov), and relevant conference proceedings. We also searched refer-
ence lists of relevant randomized controlled trials (RCTs) and
clinical reviews.
The risk of bias of individual trials was assessed16,17 with a low
risk of bias being desirable for sequence generation, allocation
concealment, and completeness of outcome data reporting. Trials in
the maintenance setting should have also been at low risk of bias for
blinding.
Progression-free survival (PFS) was the primary outcome,
allowing assessment of the effects of immediate TKI versus noClinical Lung Cancer May 2015immediate TKI without interference from the use of TKIs on
progression. Overall survival (OS) was the secondary outcome,
accepting this limitation. Data on patient characteristics, including
histology, ethnicity, EGFR mutational and smoking status, in-
terventions, and outcomes were extracted from trial reports. When
EGFR mutational status of patients was not reported it was esti-
mated based on trial characteristics.
Statistical Analysis
Because trials did not necessarily test all patients for EGFR
mutations and/or report results according to EGFR mutation status,
we used 3 analytical approaches to make maximum use of the data
available. Results were assessed for consistency and whether, taken
together, they established with greater certainty, the effects of TKIs
in patients with wild type EGFR. All interpretation was based on
the balance of the results across these 3 approaches and not on any
of the individual approaches in isolation.
Estimating the Interaction Between Treatment Effect and EGFR
Mutation Status. When possible, hazard ratio (HR) estimates of
effect and associated statistics were either extracted or estimated
from the reported analyses18-20 according to EGFR mutation status
for each trial. These were used to estimate the interaction between
treatment effect and EGFR mutational status, calculated as the ratio
of the estimated HRs within the EGFR wild type subgroup and the
EGFR mutation subgroup for each trial.14 Interaction HRs were
combined across trials using the ﬁxed-effects inverse-variance model.
Heterogeneity was assessed using c2 test and I2 statistic.21 Such
interactions are based on a comparison of the treatment effects of
the TKIs for patients with wild type and mutated EGFR within
trials. Therefore, the interactions might only be calculated for trials
in which patients were tested for EGFR mutation status and the HR
estimates for the wild type and mutation populations were reported.
They cannot be calculated for trials that recruited patients with wild
type EGFR exclusively.
Estimating the Effects of Treatment in Patients With Wild Type and
Mutated EGFR. To estimate the effect of TKI outcomes for patients
with wild type and mutated EGFR, using the maximum available
data, the trial HRs and associated statistics were combined across
trials using the ﬁxed-effects inverse-variance model. Again, we were
restricted to patients tested for EGFR mutation status, but could
include trials that exclusively recruited patients with wild type
EGFR. Heterogeneity was assessed using the c2 test and I2 statis-
tic21 and where identiﬁed, the random effects model was applied.
The absolute effect on median PFS was calculated by applying the
relevant HR to the average control group median PFS, assuming
proportional hazards.
Estimating the Effects of Treatment According to the Proportion of
Patients With Wild Type EGFR. Using metaregression we investi-
gated how increasing proportions of patients with wild type EGFR
(considered as a continuous factor) affected treatment effects. All
trials reporting overall estimates of effect were included. Estimates of
the effect of TKIs on PFS for all randomized patients were extracted
or estimated from the reported analyses.18-20 When only a small
proportion of patients had been tested for mutation status, we
Claire L. Vale et alassumed that the proportion of patients with wild type EGFR
would remain consistent across the whole trial. When no testing of
mutation status had been carried out, or reported in a trial, we
estimated the proportions of randomized patients having wild type
EGFR to be 90% in western trials and 60% in trials of East Asian
patients. We then estimated the change in treatment effect with
increasing proportions of patients with wild type EGFR.
We also explored whether the TKI used (erlotinib or geﬁtinib) or
the chemotherapy regimen used (docetaxel alone, pemetrexed alone,
or docetaxel with pemetrexed) affected the effect of TKIs. Charac-
teristics found to be important were adjusted for in the metare-
gression and explored using the F ratio.22
Results
We identiﬁed 25 potentially eligible RCTs, of TKIs as second-
line treatment (n ¼ 18) and maintenance treatment (n ¼ 7;
Figure 1).
Tyrosine Kinase Inhibitor Versus Chemotherapy in the
Second-Line Setting
Of 18 potentially eligible trials, randomizing 4456 patients, 1
trial reported no results,23 2 trials24 and NCT00536107 were not
published, and 1 randomized phase II feasibility trial never reached
the phase III stage.25 Results were based on the 14 remaining
eligible trials (4388 patients, 98% of total randomized,
Table 1).8,9,26-37 Trials compared TKIs with either docetaxel orFigure 1 Randomized Controlled Trial (RCT) Identiﬁcation,
Screening, and Inclusion
Abbreviation: NSCLC ¼ nonesmall-cell lung cancer.pemetrexed chemotherapy and were conducted between 2003 and
2012. Six trials were carried out in predominantly Asian pop-
ulations. Randomized patients had good performance status (0-2)
and median age ranged from 54.5 to 67.5 years (range, 20-88 years).
Most were men and either current or former smokers. One trial33
included considerably more women (85%) and only never-
smokers. Three trials randomized patients with wild type EGFR
exclusively.8,9,37 Five trials evaluated EGFR mutation status using a
range of methods (including DAKO EGFR Pharma DX and
Eppendorf Piezo-electric microdissector). Mutation status was not
evaluated in 5 trials. Twelve trials (3963 patients, 90% of total)
reported PFS and 14 trials (4355 patients, 99% of total) reported
OS (Tables 1 and 2).
Assessment of Risk of Bias
One trial,36 published in Chinese language, was judged to be
unclear for all domains. The remaining 13 trials were all at low risk
of bias regarding incomplete outcome data. Missing data on EGFR
mutational status largely resulted from unavailable tumor samples or
because the trials were conducted before widespread testing. All
were judged to be at low risk of bias for sequence generation. For
allocation concealment, 10 trials were judged to be at low risk of
bias and 3 were judged as unclear risk. No trials were judged to be at
high risk for any of the domains assessed (see Supplemental Table 1
in the online version).8,9,26-37 When information could not be
obtained from the publications, we contacted the authors.44
Progression-Free Survival
Interaction Between Treatment Effect and EGFR Mutation Status.
Data on the effects of TKIs compared with chemotherapy on PFS
within groups of patients with EGFR mutations and wild type
EGFR were available from 4 trials, including 442 patients with wild
type EGFR and 113 with EGFR mutations (13% of the total
randomized in all trials). There was strong evidence of an interaction
between the effect of TKIs and EGFR mutational status (interaction
HR, 2.69; 95% conﬁdence interval [CI], 1.37-5.29; P ¼ .004;
Figure 2A),8,9,27,29,31,33,35,37 with the beneﬁt of treatment of TKIs
evident only among patients with EGFR mutations. This was
consistent across trials (heterogeneity P ¼ .179; I2, 39%).
Effect of Treatment in Patients With Wild-Type and Mutated
EGFR. Results for patients with wild type EGFR were available for
9 trials and 1302 patients (30% of the total randomized in all trials).
There was evidence of a detriment with TKIs compared with
chemotherapy (HR, 1.31; 95% CI, 1.16-1.48; P < .0001;
Figure 2B), with some evidence of variation between the trial results
(heterogeneity P ¼ .09; I2, 41%). However, the effect was fairly
similar with a random-effects model (HR, 1.27; 95% CI, 1.08-
1.51; P ¼ .005). Assuming a median baseline PFS of 13 weeks,
based on the average time of PFS in the control arms of included
trials; HR, 1.31 translates to a 3-week absolute reduction in median
PFS (from 13 weeks to 10 weeks).
Four trials reported PFS for patients with EGFR mutations.
Based on these 113 patients (2% of the total randomized in all
trials), there was evidence of a beneﬁt with TKIs compared with
chemotherapy (HR, 0.34; 95% CI, 0.20-0.60; P ¼ .0002) and no
evidence of variation between the trial results (heterogeneityClinical Lung Cancer May 2015 - 175
Table 1 Trial and Patient Characteristics (Based on All Randomized Patients)
Trial
Accrual
Period Patient n TKI Control
Median
Age
(Range)
Sex (%
Female)
PS
(% 0/1) Ethnicity
Smoking
History (%
Never)
Histology (%
Adenocarinoma)
Patients With
Known EGFR
Status
(% of Total
Randomized)
EGFR
Mutation, n
(% of Total
With Known
Status)
EGFR Wild
Type, n (%
of Total With
Known
Status)
Trials of Second-
Line Treatment
SIGN26 2003-2004 141 Geﬁtinib Docetaxel 61 (29-85) 30 67 Western 25 Unknown NR NR NR
V-15-3227 2003-2006 489 (387a) Geﬁtinib Docetaxel Unknown 38 96 Asian 32 78 57 (12) 31 (55) 26 (45)
Herbst et al28 2004-2005 79 Erlotinib Docetaxel or
pemetrexed
with
bevacizumab
65.5 (40-88) 49 100 Western 13 78 30 (38) 1 (3) 29 (97)
INTEREST29 2004-2006 1466 (1316a) Geﬁtinib Docetaxel 60.5 (20-84) 35 88 Western 20 54 267 (18) 38 (14) 229 (86)
ISTANA30 2005-2006 161 Geﬁtinib Docetaxel 57.5 (20-74) 38 93 Asian 41 68 NR NR NR
Li et al36 2006-2008 98 Geﬁtinib Docetaxel Unknown Unknown Unknown Asian Unknown Unknown NR NR NR
TITAN31 2006-2010 424 Erlotinib Docetaxel or
pemetrexed
59 (22-79) 24 80 Western 17 50 160 (38) 11 (7) 149 (93)
HORG32 2006-2010 332 Erlotinib Pemetrexed 65.5 (37-86) 18 85 Western 16 77 (non-sq) NR NR NR
CTONG 08069,b 2009-2012 157 Geﬁtinib Pemetrexed 56.5 (24-78) 36 100 Asian 49 96 157 (100) Only WT
patients
157 (100)
TAILOR8,b 2007-2012 219 Erlotinib Docetaxel 66.5 (35-83) 31 91 Western 22 68
(greater % in
TKI arm)
219 (100) Only WT
patients
219 (100)
KCSG-LU08-0133 2008-2010 135 Geﬁtinib Pemetrexed 61 (30-78)
(younger in
TKI arm)
85 91 Western 100 100 71 (53) 33 (46) 38 (54)
PROSE34 2008-2012 263 Erlotinib Docetaxel or
pemetrexed
65 (33-85) 27 94 Western 14 88 (non-sq) 177 (67) 14 (8) 163 (92)
DELTA35 2009-2012 301 Erlotinib Docetaxel 67.5 (31-85) 29 96 Asian 25 69 255 51 (20) 199 (78)
Li et al37,b 2008-2014 123 Erlotinib Pemetrexed 54.5 (30-75) 36 94 Asian 26 100 123 (100) Only WT
patients
123 (100)
Total 4388 (4136) 1516 (35) 179 (12) 1332 (88)
Trials of
Maintenance
Treatment
SATURN38 2005-2008 889 Erlotinib Placebo 60 (30-83) 26 100% Western 17 45 368 (41) 40 (11) 328 (89)
IFCT-GFPC 0502
(NCT00300586)39
2006-2009 310c Erlotinib Observation 58 (36-72) 27 100% Western 9 65 114 (37) 8 (7) 106 (93)
EORTC 0802140 2004-2009 173 Geﬁtinib Placebo 61 (28-80) 23 94% Western 22 51 NR NR NR
T
K
Is
for
A
dvanced
N
SC
L
C
P
atients
W
ith
W
ild-T
ype
E
G
FR
176 -
ClinicalLung
Cancer
May
2015
Ta
bl
e
1
Co
nt
in
ue
d
Tr
ia
l
Ac
cr
ua
l
Pe
rio
d
Pa
tie
nt
n
TK
I
Co
nt
ro
l
M
ed
ia
n
Ag
e
(R
an
ge
)
Se
x
(%
Fe
m
al
e)
PS
(%
0/
1)
Et
hn
ic
ity
Sm
ok
in
g
Hi
st
or
y
(%
Ne
ve
r)
Hi
st
ol
og
y
(%
Ad
en
oc
ar
in
om
a)
Pa
tie
nt
s
W
ith
Kn
ow
n
EG
FR
St
at
us
(%
of
To
ta
l
Ra
nd
om
iz
ed
)
EG
FR
M
ut
at
io
n,
n
(%
of
To
ta
l
W
ith
Kn
ow
n
St
at
us
)
EG
FR
W
ild
Ty
pe
,n
(%
of
To
ta
lW
ith
Kn
ow
n
St
at
us
)
IN
FO
RM
41
20
08
-2
00
9
29
6
Ge
ﬁ
tin
ib
Pl
ac
eb
o
55
(2
0-
75
)
41
98
%
As
ia
n
54
71
79
(2
7)
30
(3
8)
49
(6
2)
SW
OG
S0
02
34
2
20
01
-2
00
5
26
1
Ge
ﬁ
tin
ib
Pl
ac
eb
o
61
(2
4-
81
)
37
96
%
W
es
te
rn
Un
kn
ow
n
31
NR
NR
NR
AT
LA
S4
3,
d
20
05
-2
00
8
76
8
Er
lo
tin
ib
Pl
ac
eb
o
64
(ra
ng
e
un
kn
ow
n)
48
10
0%
W
es
te
rn
16
81
34
7
(4
5)
e
52
(1
5)
29
5
(8
5)
To
ta
l
26
97
90
8
(3
4)
13
0
(1
4)
77
8
(8
6)
Ab
br
ev
ia
tio
ns
:A
TL
AS
¼
Av
as
tin
Ta
rc
ev
a
Lu
ng
Ad
en
oc
ar
ci
no
m
a
St
ud
y;
CT
ON
G
¼
Ch
in
es
e
Th
or
ac
ic
On
co
lo
gy
Gr
ou
p;
DE
LT
A
¼
Do
ce
ta
xe
la
nd
Er
lo
tin
ib
Lu
ng
Ca
nc
er
Tr
ia
l;
EG
FR
¼
ep
id
er
m
al
gr
ow
th
fa
ct
or
re
ce
pt
or
;E
OR
TC
¼
Eu
ro
pe
an
Or
ga
ni
sa
tio
n
fo
rR
es
ea
rc
h
an
d
Tr
ea
tm
en
to
f
Ca
nc
er
;H
OR
G
¼
He
lle
ni
c
On
co
lo
gy
Re
se
ar
ch
Gr
ou
p;
IF
CT
-G
FP
C
¼
Pa
rte
na
ria
tI
nt
er
gr
ou
pe
Fr
an
co
ph
on
e
de
Ca
nc
ér
ol
og
ie
Th
or
ac
iq
ue
-G
ro
up
e
Fr
an
ça
is
de
Pn
eu
m
o-
Ca
nc
ér
ol
og
ie
;I
NF
OR
M
¼
Ire
ss
a
in
NS
CL
C
FO
R
M
ai
nt
en
an
ce
;I
NT
ER
ES
T
¼
IR
ES
SA
No
n-
sm
al
l-c
el
ll
un
g
ca
nc
er
Tr
ia
lE
va
lu
at
in
g
RE
sp
on
se
an
d
Su
rv
iva
la
ga
in
st
Ta
xo
te
re
;I
ST
AN
A
¼
Ire
ss
a
as
Se
co
nd
-li
ne
Th
er
ap
y
in
Ad
va
nc
ed
NS
CL
C;
KC
SG
¼
Ko
re
an
Ca
nc
er
St
ud
y
Gr
ou
p;
no
n-
sq
¼
No
n-
Sq
ua
m
ou
s;
PR
OS
E
¼
Pr
ed
ic
tin
g
Re
sp
on
se
to
Se
co
nd
-L
in
e
Th
er
ap
y
Us
in
g
Er
lo
tin
ib
;P
S
¼
pe
rfo
rm
an
ce
st
at
us
;S
AT
UR
N
¼
Se
qu
en
tia
lT
ar
ce
va
in
Un
re
se
ct
ab
le
NS
CL
C;
SI
GN
¼
Se
co
nd
-li
ne
In
di
ca
tio
n
of
Ge
ﬁ
tin
ib
in
NS
CL
C;
SW
OG
¼
So
ut
h
W
es
tO
nc
ol
og
y
Gr
ou
p;
TA
IL
OR
¼
Ta
rc
ev
a
Ita
lia
n
Lu
ng
Op
tim
iza
tio
n
Tr
ia
l;
TI
TA
N
¼
Ta
rc
ev
a
In
Tr
ea
tm
en
to
fA
dv
an
ce
d
NS
CL
C;
TK
I¼
ty
ro
si
ne
ki
na
se
in
hi
bi
to
r;
W
T
¼
w
ild
ty
pe
.
a P
ro
gr
es
si
on
-f
re
e
su
rv
iva
la
na
lys
es
fo
r
pa
tie
nt
nu
m
be
r
in
pa
re
nt
he
se
s,
bu
t
pa
tie
nt
ch
ar
ac
te
ris
tic
s
re
po
rte
d
fo
r
al
lp
at
ie
nt
s.
b O
nl
y
ra
nd
om
ize
d
pa
tie
nt
s
w
ith
w
ild
ty
pe
EG
FR
.
c T
hr
ee
-a
rm
tri
al
in
cl
ud
in
g
46
4
ra
nd
om
ize
d
pa
tie
nt
s
bu
t
on
ly
2
ar
m
s
in
cl
ud
ed
he
re
.
d In
cl
ud
es
be
va
ci
zu
m
ab
in
bo
th
ar
m
s.
e T
ot
al
fo
r
pr
og
re
ss
io
n-
fre
e
su
rv
iva
l,
to
ta
lf
or
ov
er
al
ls
ur
viv
al
is
34
5.
Claire L. Vale et alP ¼ .26; I2, 26%; Figure 2C). Again, assuming a median PFS of 13
weeks, this translates to a 25-week increase in the absolute median
PFS (from 13 weeks to 38 weeks).
Effect of Treatment According to Proportion of Patients With Wild
Type EGFR. Twelve trials including 3963 patients reported PFS for
all patients, irrespective of EGFR status. Metaregression suggested
a decreasing effect of TKIs with increasing proportions of wild
type patients (P ¼ .014). The treatment effect predicted by the
model when 100% of patients had wild type EGFR favors
chemotherapy (HR, 1.28; 95% CI, 1.08-1.53; P ¼ .005), whereas
when 100% of patients had EGFR mutations, the model predicted
a beneﬁt of TKIs (HR, 0.45; 95% CI, 0.25-0.80; P ¼ .007;
Figure 3).8,9,26-29,31,33-35,37
Assessing Whether the Treatment Effect Varies With the
TKI or Chemotherapy Used
No differences in the treatment effects of TKIs versus chemo-
therapy were observed when trials were subdivided according to
chemotherapy used: docetaxel alone, pemetrexed alone, or docetaxel
and pemetrexed (test for between-subgroup heterogeneity P ¼ .30).
There was a difference in the treatment effect according to the TKI
used in all randomized patients (test for between-subgroup heteroge-
neity P¼ .008). However, when the analysis was adjusted to account
for substantial heterogeneity within the group of trials using geﬁtinib
(P < .0001; I2, 82%), there was no longer evidence of this difference
between the TKIs (metaregression P ¼ .24; F ratio P ¼ .18). Addi-
tionally, when the TKI type was taken into account in the metare-
gression, there was still evidence of a decreasing effect of TKIs with
increasing proportions of patients with wild type EGFR (P ¼ .043).
Overall Survival
Data on the effects of TKIs on OS within groups of patients
with EGFR mutations and wild type EGFR were available from 4
trials, including 540 patients with wild type EGFR and 97 with
EGFR mutations (15% of the total randomized in all trials). Based
on the available data, there was no evidence of an interaction
between the effect of TKIs on OS and EGFR mutational status
(interaction HR, 1.15; 95% CI, 0.60-2.18; P ¼ .68; Table 2).
This relationship appeared consistent across trials (heterogeneity
P ¼ .37; I2, 4%).
Maintenance TKI Versus No Active
Treatment
We identiﬁed 7 eligible trials. No results were available for 1
ongoing trial (NCT00153803), therefore, 6 trials38-43 were
included (2697 randomized patients, 100% of total; Table 1).
Trials were conducted between 2001 and 2009 and compared
TKIs with placebo38,40-43 or observation.39 Five trials random-
ized predominantly western patients38-40,42,43 and 1 trial ran-
domized only Chinese patients.41 Overall, randomized patients
had good performance status (0-2); with median age from 55 to
64 years (range, 20-83 years). They were mostly men and either
current or former smokers, except for 1 trial,41 in which more
than half of the included patients had never smoked. Three trials
evaluated EGFR mutation status using a range of methods
(EGFR mutation detection kit [DxS, Manchester, UK], and
sequencing of polymerase chain reaction products from exons 18Clinical Lung Cancer May 2015 - 177
Table 2 Results for Overall Survival
Trial,
n
Patient,
n
Fixed Effect Random Effect
Interaction HRa
(95% CI) P
Interaction
Heterogeneity, PHR 95% CI P HR 95% CI P
Second-Line Treatment
EGFR wild type 9 1400 1.06 0.93-1.22 .37 1.06 0.93-1.20 .37 1.15 (0.60-2.18) .68 .37
EGFR mutations 4 97 0.90 0.49-1.64 .72 0.90 0.49-1.64 .72
Maintenance Treatment
EGFR wild type 3 707 0.85 0.72-1.02 .06 0.87 0.70-1.07 .70 1.40 (0.76-2.57) .28 .49
EGFR mutations 3 120 0.59 0.33-1.05 .07 0.59 0.33-1.05 .07
Abbreviations: EGFR ¼ epidermal growth factor receptor; HR ¼ hazard ratio; TKI ¼ tyrosine kinase inhibitor.
aInteraction HR > 1 shows greater TKI beneﬁt for mutated EGFR.
TKIs for Advanced NSCLC Patients With Wild-Type EGFR
178 -to 21 of the EGFR gene). Mutation stssatus was not evaluated in
the remaining trials.
Assessment of Risk of Bias
Five trials were judged to be at low risk of bias for allocation
concealment, sequence generation, and blinding.38-41,43 OneFigure 2 (A) Tyrosine Kinase Inhibitor (TKI) Versus Chemotherapy in
and Epidermal Growth Factor Receptor (EGFR) Mutation St
Effect) Meta-Analysis of the Hazard Ratios (HRs) Represen
Type EGFR Compared With Mutated EGFR; the Horizontal L
Second-Line Setting: Effect of Treatment in 1302 Patients
Denotes the HR for That Trial With the Horizontal Lines Show
the Amount of Information Contributed by That Trial. The
Center of the Diamond Denotes the HR and the Extremitie
Setting: Effect of Treatment in 113 Patients With Mutated
Trial
KCSG LU08-01
V-15-32
INTEREST
TITAN
TKI F
.1 1
A
C
2.69 (1.37-5.29), P = .004
Heterogeneity P = .179; I2 = 39%
Favors
Favors
Favors
P
31
29
33
27
31
29
27
33
Abbreviations: CTONG ¼ Chinese Thoracic Oncology Group; DELTA ¼ Docetaxel and Erlotinib Lung
Survival against Taxotere; KCSG ¼ Korean Cancer Study Group; PROSE ¼ Predicting Response
TITAN ¼ Tarceva In Treatment of Advanced NSCLC.
Clinical Lung Cancer May 2015trial was at low risk of bias for all domains except for sequence
generation and allocation concealment, which were unclear.42
No trials were identiﬁed as being at high risk of bias. Missing
data on EGFR mutational status largely resulted from unavailable
tumor samples or because the trials were conducted before wide-
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Claire L. Vale et alProgression-Free Survival
Interaction Between Treatment Effect and EGFR
Mutation Status
Progression-free survival results were reported separately in 4
trials for wild type patients and EGFR mutation-positive patients,
908 patients (34% of the total randomized in these trials; Table 1).
There was strong evidence of an interaction between the effect of
TKIs on PFS and EGFR mutational status, with the larger effect
being observed in patients with EGFR mutations (interaction HR,
3.58; 95% CI, 2.19-5.85; P < .0001; Figure 4A).38,39,41,43 There
was some evidence of inconsistency in the effect between trials
(heterogeneity P ¼ .12; I2, 48%). However, the effect was fairly
similar with a random effects model (HR, 3.83; 95% CI, 1.85-7.95;
P ¼ .0003).
Effects of Treatment in Patients With Wild Type and
Mutated EGFR
Progression-free survival results for patients with wild type EGFR
were available from 4 trials and 778 patients. There was evidence of
a PFS beneﬁt with TKIs in patients with wild type EGFR (HR,
0.82; 95% CI, 0.71-0.96; P ¼ .01; Figure 4B) and no evidence of
variation between the trial results (heterogeneity P ¼ .90; I2, 0%).
Assuming a median PFS in the control group of 13 weeks, this
translates to an absolute improvement in median PFS of approxi-
mately 3 weeks (from 13 weeks to 16 weeks).Active Treatment: Interaction Between Treatment Effect and
for Progression-Free Survival. (B) Maintenance TKI Versus No
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180 -For patients with EGFR mutations, data were available from 4
trials but only 130 patients. Although the data available for this
analysis were very limited, there was a large PFS beneﬁt with TKIs
(HR, 0.24; 95% CI, 0.15-0.37; P < .0001; Figure 4C) but with
clear evidence of variation between the trial results (heterogeneity
P ¼ .06; I2, 58%). However, the results were similar when a
random effects model was used (HR, 0.22; 95% CI, 0.10-0.46;
P < .0001). This translated to an absolute improvement in me-
dian PFS of approximately 10 months (from 13 weeks to 13
months).
Effect of Treatment According to the Proportion of
Patients With Wild Type EGFR
Six trials (2672 patients; 99% of total randomized) reported PFS
for all patients irrespective of EGFR mutation status. The metare-
gression suggested that treatment effect varied according to the
proportion of patients with wild type EGFR (P ¼ .11). When
100% of patients had wild type EGFR, the model suggested that
there is no difference in PFS with TKIs compared with no active
treatment (HR, 0.95; 95% CI, 0.65-1.38; P ¼ .78), whereas when
100% of patients had EGFR mutations, a large beneﬁt of TKIs was
indicated (HR, 0.12; 95% CI, 0.02-0.66; P ¼ .015; Figure 5).38-43
However, the metaregression was based on only 6 trials and was
clearly limited.
Interaction Between Treatment Effect and Histology in
Patients With Wild Type EGFR
We conducted an exploratory analysis to assess whether the
beneﬁt of TKIs in patients with wild type EGFR was related to
histological type (adenocarcinoma/squamous cell carcinoma). Data
were available for 4 trials and 2129 patients (1430 adenocarcinoma;
699 squamous/other nonadenocarcinoma). There was a signiﬁcantFigure 5 Maintenance Tyrosine Kinase Inhibitor Versus No
Active Treatment: Effect of Treatment According to
the Proportion of Patients With Wild Type Epidermal
Growth Factor Receptor (EGFR) on Progression-Free
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95% CI, 1.11-1.80; P ¼ .004) with little suggestion of variation
between trials (heterogeneity P ¼ .347; I2, 3.8%). However, ben-
eﬁts of TKI were observed for patients with squamous (HR, 0.77;
95% CI, 0.64-0.92; P ¼ .004; I2, 0%; heterogeneity P ¼ .89) and
adenocarcinoma (HR, 0.59; 95% CI, 0.52-0.66; P < .0001; I2,
79%; heterogeneity P ¼ .002).
Overall Survival
Three trials reported OS according to mutation status. We found
no evidence to suggest a difference in the effect of TKIs in patients
with mutations compared with those with wild type disease
(interaction HR, 1.40; 95% CI, 0.76-2.57; P ¼ .28; Table 2). This
relationship was similar between the trials (heterogeneity P ¼ .49;
I2, 0%).
Discussion
Taken together, evidence from 3 distinct analytical approaches
suggests a difference in the effect of TKIs on PFS according to
EGFR mutation status. For patients with wild type EGFR, TKIs
seem to be an ineffective second-line treatment compared with
chemotherapy, but might be effective as maintenance treatment,
compared with no active treatment. In both settings, TKIs offer PFS
beneﬁts to patients with mutated EGFR.
Pooling the estimated interactions between treatment effects and
patient characteristics for each trial, using only within-trial infor-
mation and avoiding ecological bias,14 provides the most reliable
estimate of the relationship between the effect of TKIs and EGFR
mutation status. Nevertheless, it relies on trials reporting results for
patients with wild type EGFR and EGFR mutations separately.
Although not all trials tested patients systematically, we have no
reason to suspect selective reporting of results or selective testing of
patients, which could introduce bias. However, the precision of the
estimates of interaction was inevitably limited by the relatively low
numbers of included trials reporting results for both mutation
subgroups (trials of second line treatment, n ¼ 9, and in the
maintenance setting, n ¼ 4).
Incorporating additional data, mainly from trials that recruited
only patients with wild type EGFR, enabled us to provide further
evidence that TKIs are inferior to chemotherapy as second-line
treatment in patients with wild type EGFR, reducing median PFS
by approximately 3 weeks. As maintenance treatment, we found
that TKIs offer a modest improvement in median PFS compared
with no active treatment of approximately 3 weeks for patients with
wild type EGFR. We did, however, see some evidence of incon-
sistency between the trial results in the second-line treatment
setting, which might reﬂect the clinically heterogeneous nature of
this large group of patients. There will of course be variation in
terms of known prognostic factors such as age, tumor histology, and
stage, however, it is also possible that other, as yet undeﬁned
characteristics, might further explain this variability. Although
pooling results for patient subgroups from trials in this way might
introduce bias14 and the meta-analysis is again limited because
many trials tested only a relatively small subset of patients for
mutation status, or did not test at all, they do provide the best
available estimate of the effects of TKIs in patients with wild type
and mutated EGFR.
Claire L. Vale et alUsing metaregression, including data from all randomized pa-
tients from all eligible trials, we assessed how the proportion of
patients with wild type EGFR modiﬁed the effect of TKIs on PFS.
The results suggest that the beneﬁt of TKIs relative to chemo-
therapy on PFS diminishes with an increasing proportion of patients
with wild type EGFR. This pattern holds for the maintenance
setting, suggesting no evidence of a beneﬁt of TKIs when 100% of
patients have wild type EGFR. These metaregressions relied in part
on assumptions about the EGFR mutation status of trial pop-
ulations. Furthermore, the relationship between the effect of TKIs
and the proportion of patients with wild type EGFR might not be
representative of the true relationship between the effect of TKIs
and the mutation status of individual patients.14,45 There are clearly
limitations to this approach, not only that we had to make as-
sumptions or estimates of the proportions of patients with wild type
EGFR for a number of the trials. The relatively small number of
data points (second-line setting, n ¼ 12; maintenance setting, n ¼
6) and that in part because of estimates made, the proportions tend
to cluster around either the 60% or 90% positions, mean that the
regression model is limited. Nonetheless, this approach has allowed
us to maximize the available data to include all relevant trials, and
the results do add further support for our other analyses. Although
none of the individual approaches is without potential limitations,
using results obtained from 3 distinct methods has increased our
conﬁdence in interpreting and drawing conclusions regarding the
effect of EGFR mutation status on the response to erlotinib and
geﬁtinib in these 2 treatment settings.
These systematic reviews are the ﬁrst to have estimated the
interaction between the effects of TKIs on PFS in patients with wild
type EGFR and those with EGFR mutations appropriately and
reliably.14 Furthermore, they are the ﬁrst to have based interpreta-
tion on a range of analyses, making the best use of all available data
and to assess consistency of results. We have attempted to evaluate
the effect of treatment in wild type patients, who form the majority
of patients with NSCLC worldwide. Since the importance of acti-
vating EGFR mutations in patients’ response to TKIs were recog-
nized, research has concentrated on patients carrying such
mutations. Moreover, a recent review focused on the effect of TKIs
in mutation-positive patients and only used the limited reported
data from patients who were tested for EGFR mutations.12 Using or
estimating the proportions of patients with wild type EGFR, we
included results from all trials in a metaregression, rather than only
the minority of patients for whom results according to mutational
status were reported. We avoided estimating effects based on all
randomized patients irrespective of EGFR status, which are
potentially misleading.
Although we provided clear evidence of a difference in the effect
of TKIs according to mutation status on PFS, there was no evidence
to support a difference in their effect on OS in either treatment
setting. However, most of the included trials allowed treatment
crossover on progression, inevitably making the OS results more
difﬁcult to interpret. The full effect of TKI treatment on OS in
patients with advanced NSCLC therefore remains unclear.
In the maintenance setting, our strict eligibility criteria meant
that we included only trials in which treatment comparisons were
unconfounded. This inevitably limited the number of trials and
patients available for this analysis and hence our results must beviewed with particular caution. Furthermore, the comparator in
these trials was essentially no active treatment. It is unclear whether
the potential beneﬁt of TKIs for patients with wild type EGFR
would persist if compared for example, with pemetrexed (for pa-
tients with adenocarcinoma) as is recommended in clinical guide-
lines6-7 and NICE TA162, NCCN. We did not ﬁnd any trials that
directly compared TKIs with chemotherapy in the maintenance
setting. One 3-arm trial included in this meta-analysis compared
each of gemcitabine and erlotinib with observation alone39 but no
comparison between the 2 treatments was reported.
Currently TKIs and chemotherapy are recommended options for
second-line treatment for patients with wild type EGFR. Our results
bring this into doubt and suggest that for patients with wild type
EGFR who are well enough to receive it, chemotherapy should be
viewed as the standard of care. Furthermore, particularly outside of
East Asia, most unselected patients will have wild type EGFR.
Guidelines that recommend TKIs for unselected populations should
be reconsidered. Our results highlight the importance of suitable
biopsies and reliable EGFR mutation testing to guide optimal
clinical treatment.
Our ﬁndings regarding maintenance treatment, coupled with our
results in the second-line setting might lead us to surmise that,
compared with appropriate chemotherapy, patients with wild-type
EGFR are unlikely to beneﬁt from TKIs. However, for patients
in whom no alternative is recommended, for example, in patients
with squamous cell carcinoma, TKIs might be considered. Without
direct comparisons of TKIs with chemotherapy in this setting, the
best treatment options remain unclear.
Conclusion
There is still uncertainty regarding the best treatment option for
the overwhelming majority of advanced NSCLC patients worldwide
with wild type EGFR. However, based on these results, TKIs are
not an appropriate second-line treatment for patients who are ﬁt to
receive chemotherapy, but might offer some scope as maintenance
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Reports PFS and OS in full
INTEREST29
Full publication
Low risk Low risk NA NA Low risk Low risk
Patients were randomly assigned
with dynamic balancing
Used a centralized registration
and randomization center,
contacted by telephone, to
assign patients to a speciﬁc
treatment group
1466 Patients randomized;
1433 patients per protocol
population (OS); 1316
patients evaluable for
response population (PFS)
Reports PFS in evaluable for
response population (89% of
randomized patients) and OS
in per protocol population
(97% of randomized patients)
ISTANA30
Full publication
Low risk Unclear NA NA Low risk Low risk
Eligible patients were randomly
assigned to receive geﬁtinib or
docetaxel after stratiﬁcation for
histology, sex, PS, best response to
previous therapy, smoking history,
and participating center
NR All randomized patients are
included in the analysis
Reports PFS and OS in full
TITAN31
Full publication
Low risk Low risk NA NA Low risk Low risk
Patients who were enrolled into TITAN
were randomly assigned (1:1) using an
adaptive randomization method
(minimization as proposed by Pocock
and Simon46)
Randomization and stratiﬁcation
instructions were obtained
through a third-party telephone
interactive voice response
system
All randomized patients are
included in the analysis
Reports PFS and OS in full
HORG32
Full publication
Low risk Low risk NA NA Low risk Low risk
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Trial Sequence Generation
Allocation
Concealment
Blinding of
Participants/Personnel
Blinding of Outcome
Assessmenta
Incomplete Outcome
Data Addressed
Free of Selective
Reporting
Patients were centrally randomized by
computer at a 1:1 ratio and stratiﬁed
according to PS, disease stage, age,
and response to ﬁrst-line treatment
Patients were centrally
randomized using a computer
357 Patients randomized; 332
patients (93%) received
treatment and were analyzed
Reports time to progression
and OS in full
CTONG 08069
Abstract and slides
Low risk Low risk NA NA Low risk Low risk
Patients were randomized to receive
geﬁtinib orally or pemetrexed
Centrally randomized 161 Patients randomized; 157
(98%) were evaluable
Reports PFS and OS in full
TAILOR8
Full publication
Low risk Low risk NA NA Low risk Low risk
Treatment was randomly allocated in a
1:1 ratio using a minimization algorithm
A customized, Web-based
database was set up for
registration, randomization,
monitoring, local data entry,
and central data management
222 Patients randomized; 219
(99%) patients included in ITT
analyses
Reports PFS and OS in full
KCSG-LU08-0133
Full publication
Low risk Low risk NA NA Low risk Low risk
Patient randomization was stratiﬁed
according to ECOG PS or sex
Patients were consecutively
assigned according to a
predeﬁned computer-generated
randomization scheme
141 Patients randomized;
135 (96%) patients received
treatment and were analyzed
Reports OS and PFS in full
PROSE34
Full publication
Low risk Low risk NA NA Low risk Low risk
Treatment was randomly allocated
using a minimization algorithm, which
stratiﬁed treatment allocation according
to smoking history (never, former, or
current smokers), ECOG PS (0-1, or 2),
proteomic test classiﬁcation (poor or
good), and center
Centrally randomized 285 Patients randomized; 22
patients excluded for protocol
violations or due to not
receiving treatment; 263
(92%) patients were analyzed
Reports OS and PFS in full
DELTA35
Full publication
Low risk Low risk NA NA Low risk Low risk
Eligible patients were randomly
assigned 1:1 to erlotinib or docetaxel
using the minimization method
according to sex, PS, histology, and
institution
Centrally randomized All randomized patients are
included in the analysis
Reports OS and PFS in full
Li et al37
Full publication
Low risk Low risk NA NA Low risk Low risk
Patients were randomly assigned in a
1:1 ratio; randomization was stratiﬁed
according to sex, PS, and smoking
history using a minimization algorithm
Centrally randomized All randomized patients are
included in the analysis
Reports OS and PFS in full
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Trial Sequence Generation
Allocation
Concealment
Blinding of
Participants/Personnel
Blinding of Outcome
Assessmenta
Incomplete Outcome
Data Addressed
Free of Selective
Reporting
*Li et al36
Full publication
Unclear Unclear Unclear Unclear Unclear Unclear
Maintenance Treatment
SATURN38
Full publication
Low risk Low risk Low risk Low risk Low risk Low risk
Randomization was done using a 1:1
adaptive method using minimization
as proposed by Pocock and Simon46
Via a third-party voice
response system
Allocation was not blinded
but is unlikely to bias the
outcome of PFS
The randomization list was
not made available to the
study centers, trial monitors,
statisticians, or study sponsor
5 Patients who progressed before
randomization were not included
in the analysis of PFS (1/438
erlotinib; 4/451 placebo)
Reports PFS and OS in full
EORTC 0802140
Full publication
Low risk Low risk Low risk Low risk Low risk Low risk
Minimization with stratiﬁcation
according to stage, PS, best response,
and institution
Centralized double blind
random assignment
Double-blind Unblinding was only allowed
if the investigator needed the
information to determine
subsequent therapy
All randomized patients are
included in the analysis
Reports PFS and OS in full
IFCT-GFPC-050239
(NCT00300586)
Full publication
Low risk Low risk Low risk Low risk Low risk Low risk
Minimization adaptive randomization,
stratiﬁed according to center, sex,
histology, smoking status, and
response to ﬁrst-line CT
Randomization was
computerized and centrally
located
Lack of blinding is unlikely to
bias the outcome of PFS
Disease progression was
reviewed by a panel of
investigators who were
blinded to randomization,
independently of the
treating investigator
All randomized patients were
included in the analysis
Reports PFS and OS in full
ATLAS43
Full publication
Low risk Low risk Low risk Low risk Low risk Low risk
Patients were randomized (1:1), and
stratiﬁed according to initial
chemotherapy choice, smoking
status, and ECOG PS
Centrally randomized via an
interactive voice response
system
The study sponsor, study
investigators, and patients
were blinded to treatment
A data safety monitoring
committee monitored safety
and efﬁcacy
All randomized patients were
included
Reports PFS and OS in full
SWOG S002342
Full publication
Unclear Unclear Low risk Low risk Low risk Low risk
Randomly assigned Not reported No details reported/not
blinded but lack of blinding is
unlikely to bias the outcome
of PFS
No details reported/not
blinded but lack of blinding
is unlikely to bias the
outcome of PFS
243 Randomly assigned and
all included in analyses. An
additional 18 patients (7%)
who were randomly assigned
were found to be ineligible e
they were not analyzed
Reports PFS and OS in full
INFORM41
Full publication
Low risk Low risk Low risk Low risk Low risk Low risk
C
laire
L
.
V
ale
et
al
ClinicalLung
Cancer
May
2015 -182.e3
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Trial Sequence Generation
Allocation
Concealment
Blinding of
Participants/Personnel
Blinding of Outcome
Assessmenta
Incomplete Outcome
Data Addressed
Free of Selective
Reporting
The system generated randomization
codes based on dynamic balancing
algorithms wrt histology and
smoking history
Randomization was done
centrally by a third party
randomization center that
had no other role in the
study
Active and placebo drugs
were identical in form and
packaging to ensure blinding.
Further steps to ensure
blinding included blinding of
AstraZeneca personnel
Investigators and participants
were blinded to study
treatment until the primary
analysis of PFS was complete
All randomized patients
appear to have been included
in the analyses
Reports PFS and OS in full
Abbreviations: ATLAS ¼ Avastin Tarceva Lung Adenocarcinoma Study; CT ¼ Chemotherapy; CTONG ¼ Chinese Thoracic Oncology Group; DELTA ¼ Docetaxel and Erlotinib Lung Cancer Trial; ECOG ¼ Eastern Cooperative Oncology Group; EORTC ¼ European Organisation for
the Research and Treatment of Cancer; HORG ¼ Hellenic Oncology Research Group; IFCT-GFPC ¼ Partenariat Intergroupe Francophone de Cancérologie Thoracique - Groupe Français de Pneumo-Cancérologie; INFORM ¼ Iressa in NSCLC FOR Maintenance; INTEREST ¼
IRESSA Non-small-cell lung cancer Trial Evaluating REsponse and Survival against Taxotere; ISTANA ¼ Iressa as Second-line Therapy in Advanced NSCLC; ITT ¼ Intention to treat; KCSG ¼ Korean Cancer Study Group; OS ¼ overall survival; PFS ¼ progression-free survival;
PROSE ¼Predicting Response to Second-Line Therapy Using Erlotinib; PS ¼ performance status; SATURN ¼ Sequential Tarceva in Unresectable NSCLC; SIGN ¼ Second-line Indication of Geﬁtinib in NSCLC; SWOG ¼ South West Oncology Group; TAILOR ¼ Tarceva Italian Lung
Optimization Trial; TITAN ¼ Tarceva In Treatment of Advanced NSCLC; wrt ¼ with respect to.
Li trial published in Chinese language.
aBlinding only possible for trials comparing TKI with placebo in the maintenance setting.
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